Radiopharm has a robust pipeline. Pfizer got some good phase 1 data using pd-l1 as a target for their antibody drug conjugate. This should spell well for RAD’s Pd-l1 targeting Lu-177.
2 therapeutics in clinc 2 imaging assets in clinic 3 therapeutics going into clinic in 2025 3 more therapeutics un disclosed coming from the best cancer hospital in world Md anderson.
there’s so much excitement in radiopharm in general this stock can easily go to 10 to 20 cents in Australia this year.
from a US investor prospective at $36 million usd market cap and the 7 billion dollar lantheus putting in $10-15 million already! This is a no brainer should be trading at 7-8 cents in Australia and $15 dollars on the nasdaq.
complete diamond in the rough
RAD Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)